- Di processo
- Research on the gut microbiota is reshaping gastroenterology, butclinical application remains difficult due to heterogeneous data andevolving diagnostics. Microbiota – road to 2026 provides clinicianswith a rigorous update on dysbiosis, medication effects, and the roleof microbiota in upper gi diseases, ibs and other gut–brain disorders,diverticular disease, and debated topics like sibo and imo. Throughlectures and case-based discussions, the program strengthens critical interpretation of emerging evidence and supports evidence-based, clinically sound management.